Brent M Kuenzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5636094/publications.pdf

Version: 2024-02-01

820	687363	839539
citations	h-index	g-index
19	19	1569
docs citations	times ranked	citing authors
	citations 19	820 13 citations h-index 19 19

#	Article	lF	CITATIONS
1	Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells. Cancer Cell, 2020, 38, 672-684.e6.	16.8	216
2	An immunoproteomic approach to characterize the CAR interactome and signal osome. Science Signaling, 2019, 12, .	3.6	109
3	Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chemical Biology, 2016, 23, 1490-1503.	5.2	80
4	GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells. ACS Chemical Biology, 2014, 9, 353-358.	3 . 4	76
5	Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. ACS Chemical Biology, 2015, 10, 2680-2686.	3.4	68
6	Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nature Chemical Biology, 2017, 13, 1222-1231.	8.0	60
7	A census of pathway maps in cancer systems biology. Nature Reviews Cancer, 2020, 20, 233-246.	28.4	60
8	Interpretation of cancer mutations using a multiscale map of protein systems. Science, 2021, 374, eabf3067.	12.6	29
9	Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2018, 17, 2796-2810.	4.1	26
10	Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia. Scientific Reports, 2019, 9, 606.	3.3	21
11	Ceritinib Enhances the Efficacy of Trametinib in <i>BRAF/NRAS</i> -Wild-Type Melanoma Cell Lines. Molecular Cancer Therapeutics, 2018, 17, 73-83.	4.1	18
12	Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Molecular and Cellular Proteomics, 2018, 17, 2434-2447.	3.8	17
13	APOSTL: An Interactive Galaxy Pipeline for Reproducible Analysis of Affinity Proteomics Data. Journal of Proteome Research, 2016, 15, 4747-4754.	3.7	16
14	Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget, 2017, 8, 103014-103031.	1.8	9
15	Escape Excel: A tool for preventing gene symbol and accession conversion errors. PLoS ONE, 2017, 12, e0185207.	2.5	7
16	The Galaxy Platform for Reproducible Affinity Proteomic Mass Spectrometry Data Analysis. Methods in Molecular Biology, 2019, 1977, 249-261.	0.9	4
17	Unraveling the rewired network. Nature Chemical Biology, 2018, 14, 746-747.	8.0	2